Iovance Bio updates cervical cancer program data post FDA meeting
Category: #health  By Mateen Dalal  Date: 2019-07-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

Iovance Bio updates cervical cancer program data post FDA meeting

The innovaTIL-04 study is anticipated to register a total of 75 to 100 patients with the aim to support a BLA submission

Reports confirm that Iovance Biotherapeutics, Inc., a biotech company, has recently provided update regarding the regulatory path for LN-145 in advanced cervical cancer program, following the End of Phase 2 meeting conducted with the U.S. Food and Drug Administration.

Apparently, the FDA has acknowledged that the current innovaTIL-04 study of LN-145, a TIL treatment, might be enough for supporting enrolment in the treatment of advanced cervical cancer patients. The study is being registered with a potential definition of objective response rate stated by a Blinded Independent Review Committee as the primary endpoint.

Sources mentioned that in accordance with the recommendation of FDA, the novel version of the protocol will further describe the patient population. In the Biologics License Application, Iovance formally plans to include patients who have advanced following initial systemic therapy for metastatic or recurrent disease, which accounts for almost overall more advanced patients registered till date.

Along with this, the company had announced that the innovaTIL-04 study is anticipated to register a total of 75 to 100 patients with the aim to support a BLA submission.

According to Chief Executive Officer and President of Iovance Biotherapeutics, Maria Fardis, Ph.D., the agreement with FDA is to consider acceptability of the existing trial in patients suffering with cervical cancer considerably accelerates the way to BLA submission for LN-145. The capability to use the existing study, as well as the Breakthrough Therapy label recently granted to LN-145, enables the company to plan a route to submitting BLA in the second half of 2020.

For the uninitiated, Iovance Biotherapeutics develops innovate cancer immunotherapies that are based on tumor-infiltrating lymphocyte technology. It aims to market autologous cell therapy portfolio that strengthens the immune response of the body itself to attack blood cancers or eliminate solid tumors. The company is presently performing the key study innovaTIL-01 in patients with metastatic melanoma.

Source Credit: http://ir.iovance.com/phoenix.zhtml?c=254507&p=irol-newsArticle&ID=2402832

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Saudi Arabia aims for net-zero carbon emissions by the year 2060
Saudi Arabia aims for net-zero carbon emissions by the year 2060
By Mateen Dalal

Global oil producer, Saudi Arabia has recently stated that it intends to reach zero greenhouse gas emission levels by 2060, thereby joining the bandwagon with other 100 countries towards limiting the impact of climate change. Although the kingdom pl...

Abbott unites with Real Madrid to aid child welfare worldwide
Abbott unites with Real Madrid to aid child welfare worldwide
By Mateen Dalal

Abbott’s partnership with Real Madrid will cater to children’s education, social welfare, sports activities in around 80 countries It will also provide health and nutritional assistance to Academy teams and product development and inn...

TotalEnergies commences its UK Offshore Wind Hub in Scotland
TotalEnergies commences its UK Offshore Wind Hub in Scotland
By Mateen Dalal

French oil and gas major, TotalEnergies SE has inaugurated its UK Offshore Wind Hub in Scotland which will be part of the company's existing offshore operations center in Aberdeen and allow employees to shift from oil and gas to offshore win...